2012 (7 POSTS)

Unice KM, Monnot AD, Gaffney SH, Tvermoes BE, Thuett KA, Paustenbach DJ, Finley BL. 2012. Inorganic cobalt supplementation: Prediction of cobalt levels in whole blood and urine using a biokinetic model. Food Chem Toxicol 50(7):2456–2461; doi: 10.106/j.fct.2012.04.009. PMID: 22538081.

View Abstract

Finley BL, Monnot AD, Gaffney SH, Paustenbach DJ. 2012. Dose-response relationships for blood cobalt concentrations and health effects: A review of the literature and application of a biokinetic model. J Toxicol Environ Health B, 15(8):493–523; doi: 10.1080/10937404.2012.744287.

View Abstract

Knutsen JS, Kerger BD, Finley BL, Paustenbach DJ. 2012. A calibrated human PBPK model for benzene inhalation with urinary bladder and bone marrow compartments. Risk Anal 33 (7):1237–1251; doi: 10.1111/j.1539-6924.2012.01927.x. PMID: 23278103.

View Abstract

Mease K, Sane RS, Podila L, Taub ME. 2012. Differential selectivity of efflux transporter inhibitors in Caco-2 and MDCK-MDR1 monolayers: A strategy to assess the interaction of a new chemical entity with P-gp, BCRP and MRP2. J Pharm Sci 101(5):1888–1897; doi: 10.1002/jps.23069. PMID: 22359351.

View Abstract

Kirman CR, Hays SM, Aylward LL, Suh M, Proctor D. 2012. Physiologically-based pharmacokinetic model for mice, rats and humans orally-exposed to chromium. Presented at Society of Toxicology 51st Annual Meeting, San Francisco, CA, March 2012.

View Abstract

2011 (3 POSTS)

Thompson CPerry C, Gaylor D, Tachovsky A, Burkhalter B, Haws L. Derivation of an oral reference dose and drinking water screening level for sulfolane using benchmark dose modeling. Presented at Society of Toxicology 50th Annual Meeting, Washington DC, March 2011.

View Abstract

Wikoff DS, Thompson C, Walker N, DeVito M, Harris M, Birnbaum L, Haws L. Derivation of relative potency estimates using benchmark dose modeling: A case study with TCDF. Presented at Dioxin 2011, Brussels, Belgium, August 2011.

Covington T, Robinson P, Gearhart J. Exploring issues in simulating dermal exposure using a physiologically-based pharmacokinetic-pharmacodynamic (PBPK-PD) model for VX. Poster presented at Society of Toxicology 50th Annual Meeting, Washington, DC, March 2011.

2010 (1 POST)

Johns DO, Owens EO, Thompson CM, Sonawane B, Hattis D, Krishnan K. 2010. Physiological parameters and databases for PBPK modeling. Chapter 5 in: Quantitative Modeling in Toxicology. Krishnan K, Andersen M (eds.). Wiley, p. 107.

View Abstract

2009 (2 POSTS)

Thompson CM, Johns DO, Sonawane S, Barton HA, Hattis D, Tardif R, Krishnan K. 2009. Database for physiologically based pharmacokinetic (PBPK) modeling: Physiological parameters for healthy and health-impaired elderly. J Toxicol Environ Health B 12(1):1–24; doi: 10.1080/10937400802545060.

View Abstract

Wheeler MW, Bailer AJ. 2009. Comparing model averaging with other model selection strategies for benchmark dose estimation. Environ Ecol Stat 16:37-51; doi: 10.1007/s10651-007-0071-7.

View Abstract

2008 (7 POSTS)

DeWoskin RS, Thompson CM. 2008. Renal clearance parameters for PBPK model analysis of early lifestage differences in the disposition of environmental toxicants. Regul Toxicol Pharmacol 51(June):66–86; doi: 10.1016/j.yrtph.2008.02.005.

View Abstract

Teeguarden JG, Bogdanffy MS, Covington TR, Tan C, Jarabek AM. 2008. A PBPK model for evaluating the impact of aldehyde dehydrogenase polymorphisms on comparative rat and human nasal tissue acetaldehyde dosimetry. Inhal Toxicol 20(4):375–390; doi: 10.1080/08958370801903750.

View Abstract

Ulrich K, Hincks JS, Walsh R, Caroline Wetterstrand EM, Fidock MD, Sreckovic S, Lamb DJ, Douglas GJ, Yeadon M, Perros-Huguet C, Evans SM. 2008. Anti-inflammatory modulation of chronic airway inflammation in the murise house dust mite model. Pulmon Pharmacol Therapeut 21(4):637–647; doi: 10.1016/j.pupt.2008.02.006.

View Abstract

James HR, Barfield L, Britt JK, James RC. 2008. Worker exposure to secondhand smoke: Evaluating a prediction model. Prof Saf Sep:34-44.

View Abstract

Wheeler MW, Bailer AJ. 2008. Model averaging software for dichotomous dose response risk estimation. J Stat Software 26(5):1-15; doi: 10.18637jss.v026.i05.

View Abstract

Gearhart JM, Covington TR, Robinson PJ, Whalley CE, McGuire JM, Evans RA, et al. Simulation of VX exposure in multiple species by means of a physiologically based pharmacokinetic/pharmacodynamic model. Poster presented at the Bioscience Review Conference, Baltimore, MD, May 2008.

Thompson CM, Sonawane B, Barton HA, DeWoskin RS, Schlosser P, Lipscomb JC, Chiu W, Krishnan K. 2008. Approaches for applications of physiologically based pharmacokinetic models in risk assessment. J Toxicol Environ Health B 11(7):519–547; doi: 10.1080/10937400701724337.

View Abstract

2007 (3 POSTS)

Emond C, Raymer J, Garner E, Diliberto J, Staskal D, Birnbaum LS. A physiologically-based pharmacokinetic model for developmental exposure to PBDE-47 in rodents. Society of Toxicology 46th Annual Meeting, Charlotte, NC, March 2007.

Wheeler MW, Bailer AJ. 2007. Properties of model‐averaged BMDLs: A study of model averaging in dichotomous response risk estimation. Risk Anal 7(3):659-70; doi: 10.1111/j.1539-6924.2007.0090.x. PMID: 17640214.

View Abstract